CD34 and acute myeloid leukemia: To demonstrate the package, we applied epihet to 6 primary AML patients with silenced CEBPA gene expression (CEBPA-sil) from Glass et al.16 and 14 normal bone marrow (NBM) CD34+ cell samples from Li et al.7.